affected smooth frontline in I our workers healthcare thank grateful to you who and us our work to tirelessly we all COVID-XX today. call also The our also supported and on essential Working as communities pandemic employees, providers Jackie, sincerely we need. I'm the to pandemic those charities, our working want remarkably a employees proud ever, remain joining for the to a from help have team, the affected believe, to us serve all hospitals been has XXX% matched who and you, Thank of Tricida. are continue and acknowledge productive in generously as transition by the related as contributing donating who've made to I ways, those several masks COVID-XX which have COVID-XX local by virtually. to
potential our XXXX the approval trial. FDA the the pandemic update is Program, our August goal market me share confirmatory veverimer for launch At United I NDA of we in for the VALOR-CKD post has for date Accelerated the a let PDUFA The XX, PDUFA for the of commercial our Approval to provide preparations, brief under review XX. date NDA not and details of States. Before on believe COVID-XX goal marketing our August affected ongoing time, veverimer veverimer this the by do
the letter, late-cycle with XXXX. outcome or May Committee related NDA. discuss day to indicated FDA, our In review application, the to FDA cooperatively to We the Advisory meeting XX on with plan on the work continue and an hold that our held the matters to FDA our meeting
part issues. hold outstanding presented FDA FDA, outcome opportunity we review challenges an meeting due Accelerated trials. the does discuss data logistical magnitude Program, demonstrated TRCA-XXX the markup Approval as TRCA-XXXE the serum and and our think late-cycle indicated approval posed address on we initial by under currently of The effect to took to the to We bicarbonate, to COVID-XX. in our durability to for and it veverimer, veverimer with the rationale In why not surrogate requirements in the treatment plan the including satisfies
Under significant prescribed approval meets the clinically remain standard veverimer, that U.S. patients that through risk confident get outweighs to submission the would be for Approval the review, continues ensure that the initial while benefit the Program. our who we we FDA of its approval, have treatment. Overall, Accelerated
to marketing ongoing In as as COVID-XX been VALOR-CKD, in of turning the status pace monitoring pandemicm wake the Now of our we've the post trial, confirmatory carefully subjects the both enrollment. well trial. of the
note have that randomized requires flexibility. and every observed months, subjects three design study. only It's important not of COVID-XX related in discontinuations visits investigator the significant provides any We sites, the And scheduling study which for to
corresponding contingency and which to have study-wide we with addition, EMA integrity. this safety during preserve guidance, pandemic implemented to guidance of clinical patient well-being line is trial's and the trials in In FDA and COVID-XX a ensure conduct on
This us safety conduct assessments were and continuity the of subject study of delivery of directly guidance allows subject's drug of ensure treatment. allowed remote comps, to to
pace the a COVID-XX slowdown Regarding of occurred enrollment, the a pandemic. has result of as
screening in of enrollment monitoring are and our trial in it as our will XXXX. hope time, VALOR-CKD enrollment to state, the first we this bring to back At steady pandemic the that we subsides. complete the enrollment progress such, and appears As half
applies start launch the Now to are our that a and approach by organization, we've saying done I'd and discuss pandemic activities. COVID-XX significant our understand potential to of our of the to that launch work veverimer. data-driven that like the certainly to impact I'll we
environment have surveys, companies, conducted consider the timing evaluated surveys, to and launching our of this our plans in of scope are veverimer. own who spoken numerous contacts and launch multiple third-party carefully products to biotechnology We
and But patients, address the to supplement personal it First, to interest that The are and expense and are equipment protective healthcare medical doctor disruptions strong that therapies here way has COVID-XX significant the is the will in be unmet for use indicates physicians large new physicians of needs. health office most visits of temporary, patients that patient also stay. clear to likely of the there our provide and to elements from strained it payors is research currently telemedicine that pandemic interact. the many benefits has able system are and additional changed and particular,
And particularly community. nephrology our true is this research in indicates, the
from XX affected the in that typically per of a reduction pandemic nephrologists As year. about the at visits activity this estimated typical we an the April, has with reported April, that the patients negatively around an to in example, patient weekly They to week. relative XXX XX% offices the country surveyed practices, end see earlier week the in
XX% receptive However, when even increased the indicated prescribing the they show are they the and products, the would office. to would or survey that prescribe of nephrologists new via XX% would an results when learning about XX% more over telemedicine, product said veverimer environment, veverimer shown More profile, would also definitely current with or definitely in target consider specifically, the of nephrologists veverimer consider XX% these subsides. prescribe pandemic in prescribing to
hand, you disease. the with and chronic our encouraged to of With share target in veverimer in this or are information continue progression multitude the virtual data prelaunch person successful elicits we be thereby launch with We acidosis like to of for profile this today product type that in would kidney other while of points, activities, veverimer, setting. and even slow excited ongoing a treat enthusiasm of nephrologists, allowing from approved I to metabolic is
response XX acidosis Let science team the me session slowing We launched metabolic of Clinical presentations, after CME start from of Symposium the affairs our and progression. liaisons poster with our seven medical medical campaign. interventions March, on Meeting Spring NKF and extensive and a in CKD
activities of virtual held XXXX, well confidence, around in giving increased and we and be both person disease the events second attended, presentations of and and All head can these were that us education veverimer virtually into as effective. half
one a given meeting that medical from NGF reached participants exceptional, information. recent virtually articles Our not our important out findings nephrologists. the of with to best XX% and The of and that's MSLs nephrologists has are been reception have surveys, about the the journal or indicated sources XXX find of publications to engaging nephrologists already nearly interest and surprise, be
the to bone, to acidosis of acidosis, Presentations able CJ. new back Lancet. major of a recall, systematic on special You'll scientific and mechanism publications article analysis in JASN, publications to many kidney issues of be presented appropriate in related have metabolic CKD, course topics results back XX The kidney in acidosis clinical the a and publications and MSLs if acidosis. of congresses of range question nephrology XXXX. include wide injury nephrologists with metabolic to of and a data were veverimer veverimer, about as metabolic important rises These review induced and trial [indiscernible] effects on MSLs as to muscle at well that consequences treatment supported discuss of of facilitate metabolic health, meta with recent and exchange our we and the in scientific XXXX These significant that published early XXXE XXX a posters would about the
Kidney are Another with to at dramatic of our the due treatment Spring metabolic challenges. attempt that their is ASN, the on option which of only acidosis. acidosis. key bicarbonate of metabolic X% the of subject area This treatment multiple unmet sodium of Based taking focus significant manage over-the-counter fact sales to present an current CKD Week an and alkali and team, medical XX% has analysis, acidosis meetings or in for supplement current likely currently presentations metabolic NKF was unmet simple patients over-the-counter to been the both
hypertension, to a said, excess avoid the with is common patient, diet and First, such sodium reduced edema. as for delivers to heart failure sodium and CKD, as BiCARB bicarbonate recommended patients comorbidities, exasperating that sodium
the Second to dose ARBs, of slow prescribed sodium published be not by grams per of reduce safe treatment efficacious, excess bicarbonate progression. due which for which to publications, and at recently CKD daily and in load the for U.K., ability considered BiCARB out has a patients typically was the to the shown a is day. hypertensive to third, demonstrated efficacy medications to sodium ACEs And X.X CKD peer-reviewed or X cornerstone study the supported been are regimen
dose is the two-year recall, study double-blind may one the trial investigated of you metabolic randomized acidosis, that only a a patient the use treat placebo typical multi-center period. bicarb population BiCARB large in over controlled As to of broad sodium of
at categories a is results evidence also sodium study, effective. patients with doses X This unsuccessful any benefits in and harms. important X aged in efficacious acidosis, per or well-controlled In of bicarb be X, grams with to study, associated provides and detailing treating it of metabolic summarizing least XX as this X.X day proven not we health clear are suggest that that history for an be milestone CKD bicarb concluded produce over to did of safe, and net our may oil not cost the that
acids is They results the the objective paper the of action trial of the noted bicarbonate. binding authors metabolic function neutralizing to were recognition for a successfully reference BiCARB to that and reports of bicarbonate avoid increase could of particular pleased therapy also novel highlighted, removing In sodium veverimer interesting improve also its and with sodium both We acidosis. from quality life, of external veverimer, mechanism related new see to investigators. veverimer note they as It potential veverimer's these clinical to using that liabilities the sodium to of and ability physical this and related measures. asset, patient
event are At we the NKF that to on March, supported professional the garnered we it already on website. XXX credits X,XXX MA, HCPs accredited Progression. symposium, in Interventions Based in participants. courses livestream addition, able than enable posted that first the more CKD metabolic programs More than to acidosis and virtual completing see Slowing meeting, NKF obtain our supporting complications. two participated In programs by more supported and is be titled We additional CMA Evidence will for educational serious end the have the once program, people
of for courses HCPs over this we additional of supporting success by reaching be with the the CMA the of the goal year the XXXX. later accredited programs education X,XXX Given events, will end
treat to And the disease effort our emphasize our acidosis. has awareness The campaign. thrust to been key metabolic now turning disease to in awareness urgency
Over year, emphasizing progress treat significant metabolic of to made urgency acidosis. we've understanding past the the in and
chronic muscle length attributed health. As to as nephrologists, metabolic is worsening fact of address significant the had Clearly, the for of not have with simple medical as linked the that need. veverimer in patients physicians CKD, that acidosis. the understanding potential overwhelming to The we've prescribe progression to that treat efficacious metabolic their bone FDA approved has current discussed you urgency is primarily lack an well to among acidosis treatment at believe a and unmet past, proven safe have we this we to and to CKD
we to in message, awareness in digital and X impressions search, a channels. By disease from we from communication resulted already deliver QX XX generated million on impressions. XXXX, approximately in our well launch and Internet seeing increase metabolicacidosisinsights.com the of To puts XX% and platforms; utilized emails. awareness our to us QX three disease veverimer multiple approximately time through user our results these user targeted million of paid has goal have way distinct XXXX the community display visits to We've our This positive our nephrology efforts. Internet are media website
nephrologists of XX modifiable for CKD it agreement associated of April, showed that nephrologists independent XX% metabolic believe patients impacts of survey function. risk believe treat encouraging need are is urgent that proprietary acidosis levels progression and factor to the progression we that surveyed, completed A feel negatively also XX mortality. just XX% believed emphasize risk and CKD increased and and of is of understanding it how MA. These in
and these these March our feedback pleased advisory veverimer and nephrologists encouraged over in our that advisory session with the conducted materials include and two they from virtual board in awareness focus potential that acidosis. States are interest boards both, sessions. advisory on and a two prominent recently Together, for and and four-hour boards, treatment XX is disease by exhibited we the practicing nephrologists metabolic exceptionally a We provided April, in around also nephrolgoists United
for this key speakers leaders throughout these come Also, have various in and rest veverimer acidosis. serve of received will over planned XX opinion the that that be even potential peer-to-peer as deliver programs significant nephrologists, interest U.S. the are geographic our who regions in the to metabolic great year. of We from confidence value from interactions patients with we with greater may away CKD
health acidosis, to disease our metabolic we progress metabolic education and only economic on addition of also first made untreated for feedback potential treatment on obtained the significant a educating have efforts, and for have payers, implications In and acidosis. good coverage
we on meeting, who with our XXX at peers, is Our has met prior our our Managed It team lives. million represent to way Board in million hosted of and to a over insured day we we anticipated full XX XX call, payers, spending in the represent XXX a engaging goal unique Also approval. that our lives. payer least from XX now well last reported with collectively over that up Advisory XXX March, with approximately Market payers, meetings are
Our advisory major categories insurers, Managed all plans. board Medicaid participants of Advantage Medical, Medicare commercial, and including represented
of interventions, metabolic impacts. patient data our allowed of the Optum board veverimer on community the for generated The discussion Because look but a the currently individual payer discussion from with general, no from XX,XXX approved cost meetings and the mirror meeting economic today ad This have review of our opinions and was been of an health meeting. focus very many board is for serious the of de-identified at a participants, in-depth of current data complications ad cost that productive are a acidosis, of over-the-counter and highlights familiar database FDA the analysis close not of metabolic records. therapies in over there an chronic acidosis, and is health its outcomes payer
dialysis, the in and and with compared at about appreciative were to real each also the learn impact on times that one versus and times X% in a of interested without of costs. starting CKD increased acidosis Board sodium likelihood a CKD year patient a CKD healthcare patients acidosis. one that X.X impressive XX,XXX milliequivalent CKD and overall the are able the a healthcare to higher per mortality, And analysis MA, higher very interested with range, we keenly Therefore and the higher X.X stages, appreciate decrease covenant, metabolic wasting, showed likelihood that CKD muscle over more times more led a a period, bone Advisory monthly metabolic three data patients death, a they normal loss, were to for bicarbonate to lower were they to progression, particularly increase a expenses standby all-cause or acidosis metabolic likelihood see of They finally, to with has simple progress in provide with patient Participants two-year CKD
authorizations We a the management confirm of progress. that key various as implement utilization making board payers to may prior metabolic coverage techniques, received diagnosis participants from such decision ad also insights in the on acidosis
authorizations to On many attestation related open and via practice. instances, This pharmacy distribution, requests, use sodium providers assuming to the use to prior be are staff preferred the that our mirrors of primarily way bicarbonate accomplished this confirmation prior that sodium a We choice, office that will with able are will front, since level nephrologists bicarbonate. the retail of healthcare authorization of or allow existing comorbidities manage prior required which specialty. into in access in will of sodium we work will be ensure to
they prior an patient submit hub. the authorization system, our can electronic use prior Additionally, authorization, of through through or assistant
healthcare Our team on also reimbursement authorization of the requirements. will prior to educate managers be available field providers
we the detailing. in the model that the finally, other the the we on success first biotech and year, products are prepare we're as bearing launching mind and are of and the traditional fall. resurgence watch Thankfully, the virtual in COVID-XX can launch second And COVID-XX of potential environment, the of the of a in in our of impact to not challenges assessment possible physician reality this closely veverimer new now. launch of companies Based half of launch we on
XX% the highest territories This in We XX the plan in specialty prescribing to us the of in XX% nephrologists X,XXX to implement allow on-board initial force, will our reach States. to weeks. account coming come field the activities, launch managers key to United
commercial leadership extensive the XX implementing support directors. to business will directed team, campaign our regional expand be includes team The which efforts. of already world-class efforts these an supplement digital will reach promotional of We in our by
stage evaluate deployment field to plan the digital our and understanding of our we the commercial an launch, of our the during the force, anticipated effectiveness and XX to field of force including campaign gain commercial managers. XX sales which of initial previously they appropriate, ultimate adjust launch account as of As size the specialty
hope turn the August launching Now, a require commercial attention call drug a of pandemic, scope over the prepare our date. we emphasize what we launch detail. recognize for activities, our but greater face, of normal to every planning before XX product Geoff, new significant launching a be the of we I will We to subsiding times that even in in challenging, would I as PDUFA will
that veverimer important believe to continue specialty the We be nephrology area. in most the of therapies will one
